194 related articles for article (PubMed ID: 30274984)
21. Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity.
Abed A; Greene MK; Alsa'd AA; Lees A; Hindley A; Longley DB; McDade SS; Scott CJ
Mol Pharm; 2024 Mar; 21(3):1246-1255. PubMed ID: 38334409
[TBL] [Abstract][Full Text] [Related]
22. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rathinavelu A
Cells; 2018 Dec; 8(1):. PubMed ID: 30583560
[TBL] [Abstract][Full Text] [Related]
23. cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.
Berberich A; Schmitt LM; Pusch S; Hielscher T; Rübmann P; Hucke N; Latzer P; Heßling B; Lemke D; Kessler T; Platten M; Wick W
J Neurooncol; 2020 Jan; 146(1):9-23. PubMed ID: 31776900
[TBL] [Abstract][Full Text] [Related]
24. Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition.
Lebraud H; Noble RA; Phillips N; Heam K; Castro J; Zhao Y; Newell DR; Lunec J; Wedge SR; Heightman TD
Bioconjug Chem; 2018 Jun; 29(6):2100-2106. PubMed ID: 29851469
[TBL] [Abstract][Full Text] [Related]
25. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
[TBL] [Abstract][Full Text] [Related]
26. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Chen L; Pastorino F; Berry P; Bonner J; Kirk C; Wood KM; Thomas HD; Zhao Y; Daga A; Veal GJ; Lunec J; Newell DR; Ponzoni M; Tweddle DA
Int J Cancer; 2019 Jun; 144(12):3146-3159. PubMed ID: 30536898
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
[TBL] [Abstract][Full Text] [Related]
28. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
29. MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Song Y; Zhang L; Jiang Y; Hu T; Zhang D; Qiao Q; Wang R; Wang M; Han S
Theranostics; 2019; 9(20):6019-6030. PubMed ID: 31534534
[No Abstract] [Full Text] [Related]
30. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.
Higgins B; Glenn K; Walz A; Tovar C; Filipovic Z; Hussain S; Lee E; Kolinsky K; Tannu S; Adames V; Garrido R; Linn M; Meille C; Heimbrook D; Vassilev L; Packman K
Clin Cancer Res; 2014 Jul; 20(14):3742-52. PubMed ID: 24812409
[TBL] [Abstract][Full Text] [Related]
31. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
32. A combinatorial strategy for overcoming primary and acquired resistance of MEK inhibition in colorectal cancer.
Chen J; Dai J; Kang Z; Yang T; Zhao Q; Zheng J; Zhang X; Zhang J; Xu J; Sun G; Yang L; Yang T
Exp Cell Res; 2020 Aug; 393(1):112060. PubMed ID: 32407729
[TBL] [Abstract][Full Text] [Related]
33. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC
Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216
[TBL] [Abstract][Full Text] [Related]
34. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
Verreault M; Schmitt C; Goldwirt L; Pelton K; Haidar S; Levasseur C; Guehennec J; Knoff D; Labussière M; Marie Y; Ligon AH; Mokhtari K; Hoang-Xuan K; Sanson M; Alexander BM; Wen PY; Delattre JY; Ligon KL; Idbaih A
Clin Cancer Res; 2016 Mar; 22(5):1185-96. PubMed ID: 26482041
[TBL] [Abstract][Full Text] [Related]
37. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
38. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
39. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
40. Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
Glenn KJ; Yu LJ; Reddy MB; Fretland AJ; Parrott N; Hussain S; Palacios M; Vazvaei F; Zhi J; Tuerck D
Xenobiotica; 2016 Aug; 46(8):667-76. PubMed ID: 26586447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
